Neuromodulation using modulated pulse train

Information

  • Patent Grant
  • 12070606
  • Patent Number
    12,070,606
  • Date Filed
    Monday, December 27, 2021
    2 years ago
  • Date Issued
    Tuesday, August 27, 2024
    2 months ago
Abstract
A neuromodulation system comprises a plurality of electrical terminals configured for being respectively coupled to a plurality of electrodes, a user interface configured for receiving input from a user that selects one of a plurality of different shapes of a modulating signal and/or selects one of a plurality of different electrical pulse parameters of an electrical pulse train, neuromodulation output circuitry configured for outputting an electrical pulse train to the plurality of electrical terminals, and pulse train modulation circuitry configured for modulating the electrical pulse train in accordance with the selected shape of the modulating signal and/or selected electrical pulse parameter of the electrical pulse train.
Description
FIELD OF THE INVENTION

The present invention relates to neuromodulation systems, and more particularly, to neuromodulation system utilizing electrical pulse trains.


BACKGROUND OF THE INVENTION

Implantable neuromodulation systems have proven therapeutic in a wide variety of diseases and disorders. Pacemakers and Implantable Cardiac Defibrillators (ICDs) have proven highly effective in the treatment of a number of cardiac conditions (e.g., arrhythmias). Spinal Cord Stimulation (SCS) systems have long been accepted as a therapeutic modality for the treatment of chronic pain syndromes, and the application of tissue stimulation has begun to expand to additional applications such as angina pectoralis and incontinence. Deep Brain Stimulation (DBS) has also been applied therapeutically for well over a decade for the treatment of refractory chronic pain syndromes, and DBS has also recently been applied in additional areas such as movement disorders and epilepsy. Further, in recent investigations, Peripheral Nerve Stimulation (PNS) systems have demonstrated efficacy in the treatment of chronic pain syndromes and incontinence, and a number of additional applications are currently under investigation. Furthermore, Functional Electrical Stimulation (FES) systems, such as the Freehand system by NeuroControl (Cleveland, Ohio), have been applied to restore some functionality to paralyzed extremities in spinal cord injury patients.


These implantable neuromodulation systems typically include one or more electrode carrying modulation leads, which are implanted at the desired stimulation site, and a neuromodulator (e.g., an implantable pulse generator (IPG)) implanted remotely from the stimulation site, but coupled either directly to the neuromodulation lead(s) or indirectly to the neuromodulation lead(s) via a lead extension. The neuromodulation system may further comprise a handheld patient programmer to remotely instruct the neuromodulator to generate electrical stimulation pulses in accordance with selected stimulation parameters. The handheld programmer in the form of a remote control (RC) may, itself, be programmed by a clinician, for example, by using a clinician's programmer (CP), which typically includes a general purpose computer, such as a laptop, with a programming software package installed thereon.


Electrical modulation energy may be delivered from the neuromodulator to the electrodes in the form of a pulsed electrical waveform. Thus, modulation energy may be controllably delivered to the electrodes to modulate neural tissue. The combination of electrodes used to deliver electrical pulses to the targeted tissue constitutes an electrode combination, with the electrodes capable of being selectively programmed to act as anodes (positive), cathodes (negative), or left off (zero). In other words, an electrode combination represents the polarity being positive, negative, or zero. Other parameters that may be controlled or varied include the amplitude, duration, and rate of the electrical pulses provided through the electrode array. Each electrode combination, along with the electrical pulse parameters, can be referred to as a “neuromodulation parameter set.”


Of course, neuromodulators are active devices requiring energy for operation, and thus, the neurostimulation system may oftentimes includes an external charger to recharge a neuromodulator, so that a surgical procedure to replace a power depleted neuromodulator can be avoided. To wirelessly convey energy between the external charger and the implanted neuromodulator, the charger typically includes an alternating current (AC) charging coil that supplies energy to a similar charging coil located in or on the neurostimulation device. The energy received by the charging coil located on the neuromodulator can then be used to directly power the electronic componentry contained within the neuromodulator, or can be stored in a rechargeable battery within the neuromodulator, which can then be used to power the electronic componentry on-demand.


In the context of an SCS procedure, one or more leads are introduced through the patient's back into the epidural space, such that the electrodes carried by the leads are arranged in a desired pattern and spacing to create an electrode array. After proper placement of the leads at the target area of the spinal cord, the leads are anchored in place at an exit site to prevent movement of the leads. To facilitate the location of the neuromodulator away from the exit point of the leads, lead extensions are sometimes used. The leads, or the lead extensions, are then connected to the IPG, which can then be operated to generate electrical pulses that are delivered, through the electrodes, to the targeted spinal cord tissue. The modulation, and in the conventional case, the stimulation, creates the sensation known as paresthesia, which can be characterized as an alternative sensation that replaces the pain signals sensed by the patient. The efficacy of SCS is related to the ability to modulate the spinal cord tissue corresponding to evoked paresthesia in the region of the body where the patient experiences pain. Thus, the working clinical paradigm is that achievement of an effective result from SCS depends on the neuromodulation lead or leads being placed in a location (both longitudinal and lateral) relative to the spinal tissue such that the electrical modulation will induce paresthesia located in approximately the same place in the patient's body as the pain (i.e., the target of treatment).


Conventional neuromodulation therapies employ electrical stimulation pulse trains at low- to mid-frequencies (e.g., less than 1500 Hz) to efficiently induce desired firing rate of action potentials from electrical pulses (e.g., one pulse can induce a burst of action potentials, or multiple pulses may be temporally integrated to induce on action potential). Such stimulation pulse trains are usually tonic (i.e., the pulse amplitude, pulse rate, and pulse width are fixed). However, neuron response is a dynamic time course that can vary with the sequential stimulation, thereby limiting the volume of neural tissue that may be consistently stimulated. Furthermore, it is known that neural tissue may accommodate, adapt, and/or habituate to a continuous tonic input, resulting in a diminished neural response over time.


Recently, high frequency modulation (e.g., 1.5 KHz-50 KHz), which has been increasingly attractive in neuromodulation for pain management, is employed to block naturally occurring action potentials within neural fibers or otherwise disrupt the action potentials within the neural fibers. Although the underlying mechanisms of high frequency modulation for pain reduction are yet unclear, it has been hypothesized that there are many mechanisms that potentially play a role in reducing pain, including the depletion of neurotransmitter during the sustained modulation, desynchronized firing of multiple neurons, and generation of stochastic noise in neuronal signal transmission or lesioning of pain information. One disadvantage of high-frequency pulsed electrical energy is that it consumes an excessive amount of energy, thereby requiring the neuromodulator device to be charged more often.


Furthermore, although certain conventional stimulation parameters (e.g., pulse amplitude, pulse frequency, and pulse width) of the pulsed electrical energy, whether delivered at a low-, mid-, or high-frequency, can be varied to optimize the therapy, it may be desirable to allow the user to vary other characteristics of the pulsed electrical energy in order to further tailor the pulsed electrical energy to the volume of neural tissue to be modulated.


There, thus, remains an improved technique for delivering pulsed electrical energy to a patient.


SUMMARY OF THE INVENTION

In accordance with a first aspect of the present inventions, a neuromodulation system comprises a plurality of electrical terminals configured for being respectively coupled to a plurality of electrodes, a user interface configured for receiving input from a user that defines a shape of a modulating signal, and neuromodulation output circuitry configured for outputting an electrical pulse train to the plurality of electrical terminals. The neuromodulation system further comprises pulse train modulation circuitry configured for modulating the electrical pulse train in accordance with the defined shape of the modulating signal. In one embodiment, one of a pulse amplitude, a pulse rate, and a pulse duration of the electrical pulse train is modulated by the amplitude of the modulating signal. In another embodiment, the user input comprises a selection of one of a plurality of different predefined shapes of the modulating signal (e.g., at least two of a sinusoidal wave, a triangular wave, and a ramp wave). In still another embodiment, the user interface is configured for receiving another input from the user selecting an electrical pulse parameter of the electrical pulse train to be modulated, and the pulse train modulation circuitry is configured for modulating the selected electrical pulse parameter of the electrical pulse train in accordance with the defined shape of the modulating signal. The neuromodulation system may further comprise a casing containing the plurality of electrical terminals, the user interface, the neuromodulation output circuitry, and the electrical pulse modulation circuitry.


In accordance with a second aspect of the present inventions, a neuromodulation system comprises a plurality of electrical terminals configured for being respectively coupled to a plurality of electrodes, a user interface configured for receiving an input from a user selecting one of a plurality of different electrical pulse parameters for an electrical pulse train (e.g., at least two of a sinusoidal wave, a triangular wave, and a ramp wave), and neuromodulation output circuitry configured for outputting the electrical pulse train to the plurality of electrical terminals. The neuromodulation system further comprises pulse train modulation circuitry configured for modulating the selected electrical pulse parameter of the electrical pulse train. The neuromodulation system may further comprise a casing containing the plurality of electrical terminals, the user interface, the neuromodulation output circuitry, and the electrical pulse modulation circuitry.


In accordance with a third aspect of the present inventions, a neuromodulation system comprises a plurality of electrical terminals configured for being respectively coupled to a plurality of electrodes, neuromodulation output circuitry configured for outputting an electrical pulse train to the plurality of electrical terminals, and pulse train modulation circuitry configured for modulating a pulse rate of the electrical pulse train in accordance with a determinate modulating signal. The neuromodulation system may optionally comprise a user interface configured for receiving an input from a user defining a characteristic of the modulating signal. In one embodiment, the characteristic of the modulating signal is a shape of the modulating signal. In this case, the user input may comprise a selection of one of a plurality of different predefined shapes of the modulating signal (e.g., at least two of a sinusoidal wave, a triangular wave, and a ramp wave. The neuromodulation system may further comprise a casing containing the plurality of electrical terminals, the neuromodulation output circuitry, and the electrical pulse modulation circuitry.


In accordance with a fourth aspect of the present inventions, a neuromodulation system comprises a plurality of electrical terminals configured for being respectively coupled to a plurality of electrodes, neuromodulation output circuitry configured for outputting an electrical pulse train to the plurality of electrical terminals, and pulse train modulation circuitry configured for modulating a pulse duration of the electrical pulse train in accordance with a determinate modulating signal. The neuromodulation system may optionally comprise a user interface configured for receiving an input from a user defining a characteristic of the modulating signal. In one embodiment, the characteristic of the modulating signal is a shape of the modulating signal. In this case, the user input may comprise a selection of one of a plurality of different predefined shapes of the modulating signal (e.g., at least two of a sinusoidal wave, a triangular wave, and a ramp wave. The neuromodulation system may further comprise a casing containing the plurality of electrical terminals, the neuromodulation output circuitry, and the electrical pulse modulation circuitry.


Other and further aspects and features of the invention will be evident from reading the following detailed description of the preferred embodiments, which are intended to illustrate, not limit, the invention.





BRIEF DESCRIPTION OF THE DRAWINGS

The drawings illustrate the design and utility of preferred embodiments of the present invention, in which similar elements are referred to by common reference numerals. In order to better appreciate how the above-recited and other advantages and objects of the present inventions are obtained, a more particular description of the present inventions briefly described above will be rendered by reference to specific embodiments thereof, which are illustrated in the accompanying drawings. Understanding that these drawings depict only typical embodiments of the invention and are not therefore to be considered limiting of its scope, the invention will be described and explained with additional specificity and detail through the use of the accompanying drawings in which:



FIG. 1 is a plan view of an embodiment of a spinal cord modulation (SCM) system arranged in accordance with the present inventions;



FIG. 2 is a plan view of the SCM system of FIG. 1 in use with a patient;



FIG. 3 is a profile view of an implantable pulse generator (IPG) and percutaneous leads used in the SCM system of FIG. 1;



FIG. 4 is a plot of monophasic cathodic electrical modulation energy;



FIG. 5a is a plot of biphasic electrical modulation energy having a cathodic modulation pulse and an active charge recovery pulse;



FIG. 5b is a plot of biphasic electrical modulation energy having a cathodic modulation pulse and a passive charge recovery pulse;



FIG. 6a is a diagram illustrating a pulse amplitude of an electrical pulse train modulated with a sinusoidal wave in accordance with one modulation technique performed by the SCM system of FIG. 1;



FIG. 6b is a diagram illustrating a pulse amplitude of an electrical pulse train modulated with a triangular wave in accordance with one modulation technique performed by the SCM system of FIG. 1;



FIG. 6c is a diagram illustrating a pulse amplitude of an electrical pulse train modulated with a ramped wave in accordance with one modulation technique performed by the SCM system of FIG. 1;



FIG. 6d is a diagram illustrating a pulse amplitude of an electrical pulse train modulated with a stepped sinusoidal wave in accordance with one modulation technique performed by the SCM system of FIG. 1;



FIG. 7a is a diagram illustrating a pulse rate of an electrical pulse train modulated with a sinusoidal wave in accordance with one modulation technique performed by the SCM system of FIG. 1;



FIG. 7b is a diagram illustrating a pulse rate of an electrical pulse train modulated with a triangular wave in accordance with one modulation technique performed by the SCM system of FIG. 1;



FIG. 7c is a diagram illustrating a pulse rate of an electrical pulse train modulated with a ramped wave in accordance with one modulation technique performed by the SCM system of FIG. 1;



FIG. 8a is a diagram illustrating a pulse duration of an electrical pulse train modulated with a sinusoidal wave in accordance with one modulation technique performed by the SCM system of FIG. 1;



FIG. 8b is a diagram illustrating a pulse duration of an electrical pulse train modulated with a triangular wave in accordance with one modulation technique performed by the SCM system of FIG. 1;



FIG. 8c is a diagram illustrating a pulse duration of an electrical pulse train modulated with a ramped wave in accordance with one modulation technique performed by the SCM system of FIG. 1;



FIG. 9 is a block diagram of the internal components of the IPG of FIG. 3;



FIG. 10 is front view of a remote control (RC) used in the neuromodulation system of FIG. 1;



FIG. 11 is a block diagram of the internal components of the RC of FIG. 10;



FIG. 12 is a plan view of a programming screen generated by the RC of FIG. 10 for modulating an electrical pulse train.





DETAILED DESCRIPTION OF THE EMBODIMENTS

The description that follows relates to a spinal cord modulation (SCM) system. However, it is to be understood that while the invention lends itself well to applications in spinal cord modulation, the invention, in its broadest aspects, may not be so limited. Rather, the invention may be used with any type of implantable electrical circuitry used to stimulate tissue. For example, the present invention may be used as part of a pacemaker, a defibrillator, a cochlear stimulator, a retinal stimulator, a stimulator configured to produce coordinated limb movement, a cortical stimulator, a deep brain stimulator, peripheral nerve stimulator, microstimulator, or in any other neurostimulator configured to treat urinary incontinence, sleep apnea, shoulder sublaxation, headache, etc.


Turning first to FIG. 1, an exemplary SCM neuromodulation system 10 generally includes one or more (in this case, two) implantable modulation leads 12, an implantable pulse generator (IPG) 14, an external remote controller RC 16, a clinician's programmer (CP) 18, an External Trial Modulator (ETM) 20, and an external charger 22.


The IPG 14 is physically connected via one or more percutaneous lead extensions 24 to the neuromodulation leads 12, which carry a plurality of electrodes 26 arranged in an array. In the illustrated embodiment, the neuromodulation leads 12 are percutaneous leads, and to this end, the electrodes 26 may be arranged in-line along the neuromodulation leads 12. In alternative embodiments, the electrodes 26 may be arranged in a two-dimensional pattern on a single paddle lead. As will be described in further detail below, the IPG 14 includes pulse generation circuitry that delivers electrical modulation energy in the form of a pulsed electrical waveform (i.e., a temporal series of electrical pulses) to the electrode array 26 in accordance with a set of neuromodulation parameters.


The ETM 20 may also be physically connected via the percutaneous lead extensions 28 and external cable 30 to the neuromodulation leads 12. The ETM 20, which has similar pulse generation circuitry as the IPG 14, also delivers electrical modulation energy in the form of a pulse electrical waveform to the electrode array 26 accordance with a set of neuromodulation parameters. The major difference between the ETM 20 and the IPG 14 is that the ETM 20 is a non-implantable device that is used on a trial basis after the neuromodulation leads 12 have been implanted and prior to implantation of the IPG 14, to test the responsiveness of the stimulation that is to be provided. Thus, any functions described herein with respect to the IPG 14 can likewise be performed with respect to the ETM 20.


The RC 16 may be used to telemetrically control the ETM 20 via a bi-directional RF communications link 32. Once the IPG 14 and modulation leads 12 are implanted, the RC 16 may be used to telemetrically control the IPG 14 via a bi-directional RF communications link 34. Such control allows the IPG 14 to be turned on or off and to be programmed with different neuromodulation parameter sets. The IPG 14 may also be operated to modify the programmed neuromodulation parameters to actively control the characteristics of the electrical modulation energy output by the IPG 14. As will be described in further detail below, the CP 18 provides clinician detailed neuromodulation parameters for programming the IPG 14 and ETM 20 in the operating room and in follow-up sessions.


The CP 18 may perform this function by indirectly communicating with the IPG 14 or ETM 20, through the RC 16, via an IR communications link 36. Alternatively, the CP 18 may directly communicate with the IPG 14 or ETM 20 via an RF communications link (not shown). The clinician detailed neuromodulation parameters provided by the CP 18 are also used to program the RC 16, so that the neuromodulation parameters can be subsequently modified by operation of the RC 16 in a stand-alone mode (i.e., without the assistance of the CP 18).


The external charger 22 is a portable device used to transcutaneously charge the IPG 14 via an inductive link 38. For purposes of brevity, the details of the external charger 22 will not be described herein. Once the IPG 14 has been programmed, and its power source has been charged by the external charger 22 or otherwise replenished, the IPG 14 may function as programmed without the RC 16 or CP 18 being present.


For purposes of brevity, the details of the ETM 20 and external charger 22 will not be described herein. Details of exemplary embodiments of these devices are disclosed in U.S. Pat. No. 6,895,280, which is expressly incorporated herein by reference.


As shown in FIG. 2, the neuromodulation leads (or lead) 12 are implanted within the spinal column 42 of a patient 40. The preferred placement of the neuromodulation leads 12 is adjacent, i.e., resting near, or upon the dura, adjacent to the spinal cord area to be stimulated. The neuromodulation leads 12 will be located in a vertebral position that depends upon the location and distribution of the chronic pain. For example, if the chronic pain is in the lower back or legs, the neuromodulation leads 12 may be located in the mid- to low-thoracic region (e.g., at the T9-12 vertebral levels). Due to the lack of space near the location where the neuromodulation leads 12 exit the spinal column 42, the IPG 14 is generally implanted in a surgically-made pocket either in the abdomen or above the buttocks. The IPG 14 may, of course, also be implanted in other locations of the patient's body. The lead extensions 24 facilitate locating the IPG 14 away from the exit point of the electrode leads 12. As there shown, the CP 18 communicates with the IPG 14 via the RC 16.


Referring now to FIG. 3, the features of the neuromodulation leads 12 and the IPG 14 will be briefly described. One of the neuromodulation leads 12(1) has eight electrodes 26 (labeled E1-E8), and the other modulation lead 12(2) has eight electrodes 26 (labeled E9-E16). The actual number and shape of leads and electrodes will, of course, vary according to the intended application. The IPG 14 comprises an outer case 44 for housing the electronic and other components (described in further detail below), and a connector 46 to which the proximal ends of the neuromodulation leads 12 mates in a manner that electrically couples the electrodes 26 to the electronics within the outer case 40. The outer case 44 is composed of an electrically conductive, biocompatible material, such as titanium, and forms a hermetically sealed compartment wherein the internal electronics are protected from the body tissue and fluids. In some cases, the outer case 40 may serve as an electrode.


As will be described in further detail below, the IPG 14 includes a battery and pulse generation circuitry that delivers the electrical modulation energy in the form of one or more electrical pulse trains to the electrode array 26 in accordance with a set of neuromodulation parameters programmed into the IPG 14. Such neuromodulation parameters may comprise electrode combinations, which define the electrodes that are activated as anodes (positive), cathodes (negative), and turned off (zero), percentage of modulation energy assigned to each electrode (fractionalized electrode configurations), and electrical pulse parameters, which define the pulse amplitude (measured in milliamps or volts depending on whether the IPG 14 supplies constant current or constant voltage to the electrode array 26), pulse duration (measured in microseconds), pulse rate (measured in pulses per second), and burst rate (measured as the modulation on duration X and modulation off duration Y).


Electrical modulation will occur between two (or more) activated electrodes, one of which may be the IPG case 44. Modulation energy may be transmitted to the tissue in a monopolar or multipolar (e.g., bipolar, tripolar, etc.) fashion. Monopolar modulation occurs when a selected one of the lead electrodes 26 is activated along with the case of the IPG 14, so that modulation energy is transmitted between the selected electrode 26 and case. Bipolar modulation occurs when two of the lead electrodes 26 are activated as anode and cathode, so that modulation energy is transmitted between the selected electrodes 26. For example, electrode E3 on the first lead 12(1) may be activated as an anode at the same time that electrode E11 on the second lead 12(1) is activated as a cathode. Tripolar modulation occurs when three of the lead electrodes 26 are activated, two as anodes and the remaining one as a cathode, or two as cathodes and the remaining one as an anode. For example, electrodes E4 and E5 on the first lead 12 may be activated as anodes at the same time that electrode E12 on the second lead 12 is activated as a cathode


The modulation energy may be delivered between a specified group of electrodes as monophasic electrical energy or multiphasic electrical energy. As illustrated in FIG. 4, monophasic electrical energy takes the form of an electrical pulse train that includes either all negative pulses (cathodic), or alternatively all positive pulses (anodic).


Multiphasic electrical energy includes a series of pulses that alternate between positive and negative. For example, as illustrated in FIGS. 5a and 5b, multiphasic electrical energy may include a series of biphasic pulses, with each biphasic pulse including a cathodic (negative) modulation pulse (during a first phase) and an anodic (positive) charge recovery pulse (during a second phase) that is generated after the modulation pulse to prevent direct current charge transfer through the tissue, thereby avoiding electrode degradation and cell trauma. That is, charge is conveyed through the electrode-tissue interface via current at an electrode during a modulation period (the length of the modulation pulse), and then pulled back off the electrode-tissue interface via an oppositely polarized current at the same electrode during a recharge period (the length of the charge recovery pulse).


The second phase may have an active charge recovery pulse (FIG. 5a), wherein electrical current is actively conveyed through the electrode via current or voltage sources, and a passive charge recovery pulse, or the second phase may have a passive charge recovery pulse (FIG. 5b), wherein electrical current is passively conveyed through the electrode via redistribution of the charge flowing from coupling capacitances present in the circuit. Using active recharge, as opposed to passive recharge, allows faster recharge, while avoiding the charge imbalance that could otherwise occur. Another electrical pulse parameter in the form of an interphase can define the time period between the pulses of the biphasic pulse (measured in microseconds).


Significant to the present inventions, the SCM system 10 is capable of allowing a user to define an electrical pulse parameter (e.g., a pulse amplitude, pulse rate, and/or a pulse duration) of an electrical pulse train that is to be modulated with a determinate modulation signal. The SCM system may also be capable of allowing a user to define the shape (e.g., sinusoidal, triangular, ramp, etc) of the modulation signal that is to be used to modulate the electrical pulse train. In this manner, more flexibility is provided to the user to tailor the pulsed electrical energy to the targeted volume of neural tissue to be modulated. Furthermore, for low- or mid-frequency applications (i.e., less than 1500 Hz), accommodation of the neural tissue may be prevented or otherwise minimized without having to expend a considerable amount of energy that might otherwise occur by utilizing high-frequency electrical energy. It is also proposed that the modulation of a low- or mid-frequency pulse train may desynchronize the firing of action potentials in the neural tissue at a reduced energy consumption.


The amplitude of a relatively high frequency electrical pulse train may be modulated by a relatively low frequency modulating signal to create an electrical pulse train having an envelope that varies in accordance with the amplitude of the modulating signal (i.e., as the amplitude of the modulating signal increases, the envelope of electrical pulse train increases, and as the amplitude of the modulating signal decreases, the envelope of the electrical pulse train decreases). For example, as illustrated in FIG. 6a, the amplitude of an electrical pulse train can be modulated by a sinusoidal modulating signal to create an electrical pulse train with a sinusoid shaped envelope. As illustrated in FIG. 6b, the amplitude of an electrical pulse train can be modulated by a triangular modulating signal to create an electrical pulse train with a triangle shaped envelope. As illustrated in FIG. 6c, the amplitude of an electrical pulse train can be modulated by a ramped modulating signal to create an electrical pulse train with a ramp shaped envelope. Although the ramped modulating signal is shown as being linearly increasing, the ramped modulating signal may alternatively be linearly decreasing, or even non-linearly increasing or decreasing (e.g., exponential). The electrical pulse train can be alternately turned on and off to create a modulated bursted electrical pulse train. For example, as illustrated in FIG. 6d, the amplitude of an electrical pulse train can be modulated by the combination of a sinusoidal modulating signal and a stepped signal to create a bursted electrical pulse train with a sinusoid shaped envelope.


The pulse rate of a relatively high frequency electrical pulse train may be modulated by a relatively low frequency modulating signal to create an electrical pulse train having a pulse rate that varies in accordance with the amplitude of the modulating signal (i.e., as the amplitude of the modulating signal increases, the pulse rate increases, and as the amplitude of the modulating signal decreases, the pulse rate decreases). For example, as illustrated in FIG. 7a, the pulse rate of an electrical pulse train can be modulated by a sinusoidal modulating signal to create an electrical pulse train having a pulse rate that varies in accordance with the amplitude of the sinusoidal modulating signal. As illustrated in FIG. 7b, the pulse rate of an electrical pulse train can be modulated by a triangular modulating signal to create an electrical pulse train having a pulse rate that varies in accordance with the amplitude of the triangular modulating signal. As illustrated in FIG. 7c, the pulse rate of an electrical pulse train can be modulated by a ramped modulating signal to create an electrical pulse train having a pulse rate that varies in accordance with the amplitude of the ramped modulating signal. Although a single timing channel is utilized to create the modulated electrical pulse trains illustrated in FIGS. 7a-7c, electrical pulse trains with different pulse rates can be bursted on and off in multiple timing channels to create a single electrical pulse train with a modulated pulse rate, as described in U.S. Provisional Patent Application Ser. No. 61/768,286, entitled “Multi-Channel Neuromodulation System Having Frequency Modulated Stimulation,” which is expressly incorporated herein by reference.


The pulse duration of a relatively high frequency electrical pulse train may be modulated by a relatively low frequency modulating signal to create an electrical pulse train having a pulse duration that varies in accordance with the amplitude of the modulating signal (i.e., as the amplitude of the modulating signal increases, the pulse duration increases, and as the amplitude of the modulating signal decreases, the pulse duration decreases). For example, as illustrated in FIG. 8a, the pulse duration of an electrical pulse train can be modulated by a sinusoidal modulating signal to create an electrical pulse train having a pulse duration that varies in accordance with the amplitude of the sinusoidal modulating signal. As illustrated in FIG. 8b, the pulse duration of an electrical pulse train can be modulated by a triangular modulating signal to create an electrical pulse train having a pulse duration that varies in accordance with the amplitude of the triangular modulating signal. As illustrated in FIG. 8c, the pulse duration of an electrical pulse train can be modulated by a ramped modulating signal to create an electrical pulse train having a pulse duration that varies in accordance with the amplitude of the ramped modulating signal.


Although the modulations of the electrical pulse trains illustrated above are biphasic in nature, it should be appreciated that the modulation of an electrical pulse train can be monophasic in nature; for example, by modulating the amplitudes of only the cathodic phases of the electrical pulse train.


Turning next to FIG. 9, the main internal components of the IPG 14 will now be described. The IPG 14 includes neuromodulation output circuitry 50 configured for generating electrical modulation energy in accordance with a defined pulsed waveform having a specified pulse amplitude, pulse rate, pulse width, pulse shape, and burst rate under control of control logic 52 over data bus 54. Control of the pulse rate and pulse width of the electrical waveform is facilitated by timer logic circuitry 56, which may have a suitable resolution, e.g., 10 μs. The neuromodulation energy generated by the neuromodulation output circuitry 50 is output via capacitors C1-C16 to electrical terminals 58 corresponding to the electrodes 26. The neuromodulation circuitry 50 may either comprise independently controlled current sources for providing modulation pulses of a specified and known amperage to or from the electrodes 26, or independently controlled voltage sources for providing modulation pulses of a specified and known voltage at the electrodes 26.


Any of the N electrodes may be assigned to up to k possible groups or timing “channels.” In one embodiment, k may equal four. The timing channel identifies which electrodes are selected to synchronously source or sink current to create an electric field in the tissue to be stimulated. Amplitudes and polarities of electrodes on a channel may vary, e.g., as controlled by the RC 16. External programming software in the CP 18 is typically used to set neuromodulation parameters including electrode polarity, amplitude, pulse rate and pulse duration for the electrodes of a given channel, among other possible programmable features.


The N programmable electrodes can be programmed to have a positive (sourcing current), negative (sinking current), or off (no current) polarity in any of the k channels. Moreover, each of the N electrodes can operate in a multipolar (e.g., bipolar) mode, e.g., where two or more electrode contacts are grouped to source/sink current at the same time. Alternatively, each of the N electrodes can operate in a monopolar mode where, e.g., the electrode contacts associated with a channel are configured as cathodes (negative), and the case electrode (i.e., the IPG case) is configured as an anode (positive).


Further, the amplitude of the current pulse being sourced or sunk to or from a given electrode may be programmed to one of several discrete current levels, e.g., between 0 to 10 mA in steps of 0.1 mA. Also, the pulse duration of the current pulses is preferably adjustable in convenient increments, e.g., from 0 to 1 milliseconds (ms) in increments of 10 microseconds (μs). Similarly, the pulse rate is preferably adjustable within acceptable limits, e.g., from 0 to 50000 pulses per second (pps). Other programmable features can include slow start/end ramping, burst modulation cycling (on for X time, off for Y time), interphase, and open or closed loop sensing modes.


The operation of this neuromodulation output circuitry 50, including alternative embodiments of suitable output circuitry for performing the same function of generating modulation pulses of a prescribed amplitude and duration, is described more fully in U.S. Pat. Nos. 6,516,227 and 6,993,384, which are expressly incorporated herein by reference.


The IPG 14 further comprises pulse train modulation circuitry 60 configured for using predeterminate modulation signals (e.g., the modulating signals illustrated in FIGS. 6-8 to modulate electrical pulse train output by the neuromodulation output circuitry 50 to the electrical terminals 58. In response to user input, as will be described in further detail below, the modulation circuitry 60 may advantageously select the particular electrical parameter (e.g., pulse amplitude, pulse rate, and/or pulse duration) of the electrical pulse train and/or select the shape of the modulation signal (e.g., sinusoidal, triangular, ramped, etc.) used to modulate the electrical pulse train. The modulation circuitry 60 may be analog-based and incorporated into the output of the neuromodulation output circuitry 50 and/or may be digitally-based and incorporated into the control logic 52 and timer logic circuitry 56.


The IPG 14 further comprises monitoring circuitry 62 for monitoring the status of various nodes or other points 64 throughout the IPG 14, e.g., power supply voltages, temperature, battery voltage, and the like. The IPG 14 further comprises processing circuitry in the form of a microcontroller (μc) 66 that controls the control logic over data bus 68, and obtains status data from the monitoring circuitry 62 via data bus 70. The IPG 14 additionally controls the timer logic 56. The IPG 14 further comprises memory 72 and oscillator and clock circuitry 74 coupled to the microcontroller 66. The microcontroller 66, in combination with the memory 72 and oscillator and clock circuitry 74, thus comprise a microprocessor system that carries out a program function in accordance with a suitable program stored in the memory 72. Alternatively, for some applications, the function provided by the microprocessor system may be carried out by a suitable state machine.


Thus, the microcontroller 66 generates the necessary control and status signals, which allow the microcontroller 66 to control the operation of the IPG 14 in accordance with a selected operating program and neuromodulation parameters stored in the memory 72. In controlling the operation of the IPG 14, the microcontroller 66 is able to individually generate an electrical pulse train at the electrodes 26 using the neuromodulation output circuitry 50, in combination with the control logic 52 and timer logic 56, thereby allowing each electrode 26 to be paired or grouped with other electrodes 26, including the monopolar case electrode. In accordance with neuromodulation parameters stored within the memory 72, the microcontroller 66 may control the polarity, amplitude, rate, pulse duration and timing channel through which the modulation pulses are provided.


Thus, it can be appreciated that, under control of the microcontroller 66, the neuromodulation output circuitry 50 is configured for outputting a k number of individual electrical pulse trains respectively in a k number of timing channels to the electrical terminals 58. In the IPG 14, up to four stimulation programs may be stored in the memory 72, with each stimulation program having four timing channels. Thus, each modulation program defines four sets of neuromodulation parameters for four respective timing channels. Of course, the IPG 14 may have less or more than four modulation programs, and less or more than four timing channels for each modulation program. Significantly, the microcontroller 66 controls the modulation circuitry 60 in a manner that, for each timing channel, modulates the electrical pulse train in accordance with the electrical pulse parameter and/or shape of the modulating signal selected by the user.


The IPG 14 further comprises an alternating current (AC) receiving coil 76 for receiving programming data (e.g., the operating program, neuromodulation parameters, electrical parameters to be modulated, and/or the shape of the modulating signal) from the RC 16 (shown in FIG. 2) in an appropriate modulated carrier signal, and charging and forward telemetry circuitry 78 for demodulating the carrier signal it receives through the AC receiving coil 76 to recover the programming data, which programming data is then stored within the memory 72, or within other memory elements (not shown) distributed throughout the IPG 14.


The IPG 14 further comprises back telemetry circuitry 60 and an alternating current (AC) transmission coil 82 for sending informational data sensed through the monitoring circuitry 62 to the RC 16. The back telemetry features of the IPG 14 also allow its status to be checked. For example, when the RC 16 initiates a programming session with the IPG 14, the capacity of the battery is telemetered, so that the external programmer can calculate the estimated time to recharge. Any changes made to the current stimulus parameters are confirmed through back telemetry, thereby assuring that such changes have been correctly received and implemented within the implant system. Moreover, upon interrogation by the RC 16, all programmable settings stored within the IPG 14 may be uploaded to the RC 16. Significantly, the back telemetry features allow raw or processed electrical parameter data (or other parameter data) previously stored in the memory 72 to be downloaded from the IPG 14 to the RC 16, which information can be used to track the physical activity of the patient.


The IPG 14 further comprises a rechargeable power source 84 and power circuits 86 for providing the operating power to the IPG 14. The rechargeable power source 84 may, e.g., comprise a lithium-ion or lithium-ion polymer battery. The rechargeable battery 84 provides an unregulated voltage to the power circuits 86. The power circuits 86, in turn, generate the various voltages 88, some of which are regulated and some of which are not, as needed by the various circuits located within the IPG 14. The rechargeable power source 84 is recharged using rectified AC power (or DC power converted from AC power through other means, e.g., efficient AC-to-DC converter circuits, also known as “inverter circuits”) received by the AC receiving coil 76. To recharge the power source 84, an external charger (not shown), which generates the AC magnetic field, is placed against, or otherwise adjacent, to the patient's skin over the implanted IPG 14. The AC magnetic field emitted by the external charger induces AC currents in the AC receiving coil 76. The charging and forward telemetry circuitry 78 rectifies the AC current to produce DC current, which is used to charge the power source 84. While the AC receiving coil 76 is described as being used for both wirelessly receiving communications (e.g., programming and control data) and charging energy from the external device, it should be appreciated that the AC receiving coil 76 can be arranged as a dedicated charging coil, while another coil, such as coil 82, can be used for bi-directional telemetry.


It should be noted that the diagram of FIG. 9 is functional only, and is not intended to be limiting. Those of skill in the art, given the descriptions presented herein, should be able to readily fashion numerous types of IPG circuits, or equivalent circuits, that carry out the functions indicated and described, which functions include not only producing a stimulus current or voltage on selected groups of electrodes, but also the ability to measure electrical parameter data at an activated or non-activated electrode.


Additional details concerning the above-described and other IPGs may be found in U.S. Pat. No. 6,516,227, U.S. Patent Publication No. 2003/0139781, and U.S. patent application Ser. No. 11/138,632, entitled “Low Power Loss Current Digital-to-Analog Converter Used in an Implantable Pulse Generator,” which are expressly incorporated herein by reference. It should be noted that rather than an IPG, the SCM system 10 may alternatively utilize an implantable receiver-stimulator (not shown) connected to the neuromodulation leads 12. In this case, the power source, e.g., a battery, for powering the implanted receiver, as well as control circuitry to command the receiver-stimulator, will be contained in an external controller inductively coupled to the receiver-stimulator via an electromagnetic link. Data/power signals are transcutaneously coupled from a cable-connected transmission coil placed over the implanted receiver-stimulator. The implanted receiver-stimulator receives the signal and generates the modulation in accordance with the control signals.


Referring now to FIG. 10, one exemplary embodiment of an RC 16 is described. As previously discussed, the RC 16 is capable of communicating with the IPG 14, CP 18, or ETS 20. The RC 16 comprises a casing 100, which houses internal componentry (including a printed circuit board (PCB)), and a lighted display screen 102 and button pad 104 carried by the exterior of the casing 100. In the illustrated embodiment, the display screen 102 is a lighted flat panel display screen, and the button pad 104 includes a membrane switch with metal domes positioned over a flex circuit, and a keypad connector connected directly to a PCB. In an optional embodiment, the display screen 102 has touchscreen capabilities. The button pad 104 includes a multitude of buttons 106, 108, 110, and 112, which allow the IPG 14 to be turned ON and OFF, provide for the adjustment or setting of neuromodulation parameters within the IPG 14, and provide for selection between screens. The button pad 104 also allows the user to select the electrical pulse parameters to be modulated and/or the shape of the modulating signal used to modulate the electrical pulse train, as will be described in further detail below.


In the illustrated embodiment, the button 106 serves as an ON/OFF button that can be actuated to turn the IPG 14 ON and OFF. The button 108 serves as a select button that allows the RC 106 to switch between screen displays and/or parameters. The buttons 110 and 112 serve as up/down buttons that can be actuated to increase or decrease any of stimulation parameters of the pulse generated by the IPG 14, including the pulse amplitude, pulse width, and pulse rate. For example, the selection button 108 can be actuated to place the RC 16 in a “Pulse Amplitude Adjustment Mode,” during which the pulse amplitude can be adjusted via the up/down buttons 110, 112, a “Pulse Width Adjustment Mode,” during which the pulse width can be adjusted via the up/down buttons 110, 112, and a “Pulse Rate Adjustment Mode,” during which the pulse rate can be adjusted via the up/down buttons 110, 112. Alternatively, dedicated up/down buttons can be provided for each stimulation parameter. Rather than using up/down buttons, any other type of actuator, such as a dial, slider bar, keypad, or touch screen can be used to increment or decrement the stimulation parameters.


The selection button 108 can also be actuated to place the RC 16 in an “pulse train modulation mode” that allows a user modulate the electrical pulse train output by the IPG 14 in one of the timing channels and to select the electrical pulse parameter to be modulated and/or the shape of the modulating signal. For example, referring to FIG. 12, a programming screen 150 includes a modulation shape box 152 that includes a sinusoidal wave 154a, a triangular wave 154b, and a ramped wave 154c, and corresponding check boxes, any of which can be selected by the user using the button pad 104 to select the shape of the modulating signal used to modulate the electrical pulse train. Optionally, the programming screen 150 has a modulating parameter control (not shown) that allows the user to specify modulation parameters (e.g., upper and lower limit of the modulation shape, period of modulating signal, such as the sinusoidal wave, slope of a ramped wave, etc. The programming screen 150 also includes a modulated electrical pulse parameter box 156 that includes a pulse amplitude check box 158a, a pulse rate check box 158b, and a pulse duration check box 158c, any combination of which can be checked using the button pad 104 to allow the user to select the electrical pulse parameters of the electrical pulse train to be modulated. The programming screen 150 also includes an ON/OFF check box 160 that can be checked to turn the modulation feature on and unchecked to turn the modulation feature off. When the feature is turned on, the IPG 14 will modulate the selected electrical pulse parameter or parameters of the electrical pulse train using the modulating signal with the selected shape. The buttons 110 and 112 serve as up/down buttons that can be actuated to increase or decrease the amplitude of the modulating signal.


Although the foregoing programming functions have been described as being at least partially implemented in the RC 16, it should be noted that these techniques may be at least, in part, be alternatively or additionally implemented in the CP 18. Those skilled in the art will be able to fashion appropriate circuitry, whether embodied in digital circuits, analog circuits, software and/or firmware, or combinations thereof, in order to accomplish the desired functions.


Although particular embodiments of the present inventions have been shown and described, it will be understood that it is not intended to limit the present inventions to the preferred embodiments, and it will be obvious to those skilled in the art that various changes and modifications may be made without departing from the spirit and scope of the present inventions. Thus, the present inventions are intended to cover alternatives, modifications, and equivalents, which may be included within the spirit and scope of the present inventions as defined by the claims.

Claims
  • 1. A method for delivering neuromodulation energy using a neuromodulator device, comprising: outputting the neuromodulation energy from neuromodulation output circuitry of the neuromodulator device according to a waveform having a parameter modulated by a modulating signal; andreceiving, using a programming device, at least one of a selection of the modulating signal from a plurality of modulating signals or a selection of the modulated parameter from a plurality of parameters of the waveform.
  • 2. The method of claim 1, comprising receiving the selection of the modulating signal from the plurality of modulating signals.
  • 3. The method of claim 2, further comprising receiving the selection of the modulated parameter from the plurality of parameters of the waveform.
  • 4. The method of claim 2, comprising receiving the selection of the modulating signal from the plurality of modulating signals including at least one of a sinusoidal modulation signal, a triangular modulation signal, a ramped modulation signal, or a stepped sinusoidal modulation signal.
  • 5. The method of claim 2, wherein the plurality of modulating signals has a plurality of respective shapes, and receiving the selection of the modulating signal from the plurality of modulating signals comprises: displaying, using a user interface of the programming device, the plurality of respective shapes of the plurality of modulating signals; andreceiving, using the user interface, a selection of a shape from the displayed plurality of respective shapes.
  • 6. The method of claim 1, comprising receiving the selection of the modulated parameter from the plurality of parameters of the waveform.
  • 7. The method of claim 6, wherein outputting the electrical neuromodulation energy comprises outputting an electrical pulse train.
  • 8. The method of claim 7, receiving the selection of the modulated parameter from the plurality of parameters of the waveform comprises: displaying, using a user interface of the programming device, a plurality of pulse parameters of the electrical pulse train including at least one of a pulse amplitude, a pulse duration, or a pulse rate; andreceiving, using the user interface, the selection of the modulated parameter from the displayed plurality of pulse parameters.
  • 9. A system for delivering neuromodulation energy using a neuromodulator device, comprising: a programming device configured to:communicate with the neuromodulator device;control the delivery of the neuromodulation energy from the neuromodulator device according to a waveform having a parameter modulated by a modulating signal; andreceive at least one of a selection of the modulating signal from a plurality of modulating signals or a selection of the modulated parameter from a plurality of parameters of the waveform.
  • 10. The system of claim 9, wherein the programming device comprises a user interface configured to receive the at least one of the selection of the modulating signal from the plurality of modulating signals or the selection of the modulated parameter from the plurality of parameters of the waveform.
  • 11. The system of claim 10, wherein the user interface is configured to receive the selection of the modulating signal from the plurality of modulating signals.
  • 12. The system of claim 11, wherein the user interface is configured to receive the selection of the modulating signal from the plurality of modulating signals and the selection of the modulated parameter from the plurality of parameters of the waveform.
  • 13. The system of claim 11, wherein the user interface is configured to: display a plurality of respective shapes of the plurality of modulating signals; andreceive a selection of a shape from the displayed plurality of respective shapes as the selection of the modulating signal.
  • 14. The system of claim 13, wherein the user interface is configured to display the plurality of respective shapes of the plurality of modulating signals including at least one of a sinusoidal modulation signal, a triangular modulation signal, a ramped modulation signal, or a stepped sinusoidal modulation signal.
  • 15. The system of claim 10, wherein the user interface is configured to receive the selection of the modulated parameter from the plurality of parameters of the waveform.
  • 16. The system of claim 15, wherein the programming device is configured to control the delivery of the neuromodulation energy in a form of an electrical pulse train.
  • 17. The system of claim 16, wherein the user interface is configured to: display a plurality of pulse parameters of the electrical pulse train including at least one of a pulse amplitude, a pulse duration, or a pulse rate; andreceive a selection of a pulse parameter from the displayed plurality of pulse parameters as the selection of the modulated parameter.
  • 18. A non-transitory machine-readable medium including instructions, which when executed by a machine, cause the machine to perform a method for delivering neuromodulation energy using a neuromodulator device, the method comprising: controlling the delivery of the neuromodulation energy from the neuromodulator device according to a waveform having a parameter modulated by a modulating signal; andreceiving at least one of a selection of the modulating signal from a plurality of modulating signals or a selection of the modulated parameter from a plurality of parameters of the waveform.
  • 19. The non-transitory machine-readable medium of claim 18, comprising receiving the selection of the modulating signal from the plurality of modulating signals using a user interface, wherein the plurality of modulating signals has a plurality of respective shapes, and receiving the selection of the modulating signal from the plurality of modulating signals comprises: displaying the plurality of respective shapes of the plurality of modulating signals; andreceiving a selection of a shape from the displayed plurality of respective shapes.
  • 20. The non-transitory machine-readable medium of claim 18, comprising receiving the selection of the modulated parameter from the plurality of parameters of the waveform using a user interface, wherein controlling the delivery of the neuromodulation energy comprises controlling delivery of an electrical pulse train, and receiving the selection of the modulated parameter from the plurality of parameters of the waveform comprises: displaying a plurality of pulse parameters of the electrical pulse train including at least one of a pulse amplitude, a pulse duration, or a pulse rate; andreceiving the selection of the modulated parameter from the displayed plurality of pulse parameters.
RELATED APPLICATION DATA

The present application is a continuation of U.S. application Ser. No. 16/686,956, filed Nov. 18, 2019, which is a continuation of U.S. application Ser. No. 15/615,046, filed Jun. 6, 2017, now issued as U.S. Pat. No. 10,507,328, which is a continuation of U.S. application Ser. No. 15/426,776, filed Feb. 7, 2017, now issued as U.S. Pat. No. 10,118,040, which is a continuation of U.S. application Ser. No. 14/920,229, filed Oct. 22, 2015, now issued as U.S. Pat. No. 9,700,725, which is a continuation of U.S. application Ser. No. 14/195,632, filed Mar. 3, 2014, now issued as U.S. Pat. No. 9,174,053, which claims the benefit under 35 U.S.C. § 119 to U.S. provisional patent application Ser. No. 61/774,835, filed Mar. 8, 2013. The foregoing applications are hereby incorporated by reference into the present application in their entirety.

US Referenced Citations (292)
Number Name Date Kind
4255790 Hondeghem Mar 1981 A
4338945 Kosugi et al. Jul 1982 A
4398537 Holmbo Aug 1983 A
4592359 Galbraith Jun 1986 A
4931858 Honjo et al. Jun 1990 A
4935674 Rodriguez-cavazos Jun 1990 A
5300096 Hall et al. Apr 1994 A
5360437 Thompson Nov 1994 A
5369224 Miyata Nov 1994 A
5381524 Lewis et al. Jan 1995 A
5576979 Lewis et al. Nov 1996 A
5603726 Schulman et al. Feb 1997 A
5713937 Nappholz et al. Feb 1998 A
5724985 Snell et al. Mar 1998 A
5725560 Brink Mar 1998 A
5782874 Loos Jul 1998 A
5938690 Law et al. Aug 1999 A
5941906 Barreras, Sr. et al. Aug 1999 A
6246912 Sluijter et al. Jun 2001 B1
6266566 Nichols et al. Jul 2001 B1
6289247 Faltys et al. Sep 2001 B1
6516227 Meadows et al. Feb 2003 B1
6675046 Holsheimer Jan 2004 B2
6895280 Meadows et al. May 2005 B2
6993384 Bradley et al. Jan 2006 B2
7003349 Andersson et al. Feb 2006 B1
7076307 Boveja et al. Jul 2006 B2
7228179 Van Campen et al. Jun 2007 B2
7317948 King et al. Jan 2008 B1
7333856 Er et al. Feb 2008 B1
7333857 Campbell Feb 2008 B2
7539538 Parramon et al. May 2009 B2
7627384 Ayal et al. Dec 2009 B2
7650184 Walter Jan 2010 B2
7664849 Chandler et al. Feb 2010 B1
7783353 Libbus et al. Aug 2010 B2
7826901 Lee et al. Nov 2010 B2
7979119 Kothandaraman et al. Jul 2011 B2
7979133 Feler et al. Jul 2011 B2
7983762 Gliner et al. Jul 2011 B2
7987000 Moffitt et al. Jul 2011 B2
8010198 Libbus et al. Aug 2011 B2
8019439 Kuzma et al. Sep 2011 B2
8036754 Lee et al. Oct 2011 B2
8160328 Goetz et al. Apr 2012 B2
8170675 Alataris et al. May 2012 B2
8175705 Libbus May 2012 B2
8180129 Goetz et al. May 2012 B2
8209021 Alataris et al. Jun 2012 B2
8224453 De Ridder Jul 2012 B2
8249711 Libbus et al. Aug 2012 B2
8255057 Fang et al. Aug 2012 B2
8285389 Libbus et al. Oct 2012 B2
8340775 Cullen et al. Dec 2012 B1
8355797 Caparso et al. Jan 2013 B2
8359102 Alataris et al. Jan 2013 B2
8359103 Alataris et al. Jan 2013 B2
8380318 Kishawi et al. Feb 2013 B2
8396559 Alataris et al. Mar 2013 B2
8401653 Libbus et al. Mar 2013 B2
8412345 Moffitt Apr 2013 B2
8423147 Alataris et al. Apr 2013 B2
8437857 Moffitt et al. May 2013 B2
8455716 Huang et al. Jun 2013 B2
8504147 Deem et al. Aug 2013 B2
8560080 Goetz Oct 2013 B2
8594785 Bradely Nov 2013 B2
8615300 Feler et al. Dec 2013 B2
8644947 Zhu et al. Feb 2014 B2
8660653 Kothandaraman Feb 2014 B2
8670831 Wacnik et al. Mar 2014 B2
8676329 Wacnik et al. Mar 2014 B2
8676331 Parker Mar 2014 B2
8692843 Bloemer Apr 2014 B2
8694104 Libbus et al. Apr 2014 B2
8694113 Smoorenburg Apr 2014 B2
8700178 Anderson Apr 2014 B2
8706250 Zhu et al. Apr 2014 B2
8731675 Ranu et al. May 2014 B2
8751009 Wacnik Jun 2014 B2
8788048 Bennett et al. Jul 2014 B2
8788054 Kothandaraman et al. Jul 2014 B2
8798755 Grill et al. Aug 2014 B2
8874211 Libbus et al. Oct 2014 B2
8649874 Alataris et al. Dec 2014 B2
8909350 Lee Dec 2014 B2
9138582 Doan Sep 2015 B2
9174053 Zhu Nov 2015 B2
9238138 Lee et al. Jan 2016 B2
9265948 Libbus et al. Feb 2016 B2
9339655 Carbunaru May 2016 B2
9358391 Zhu et al. Jun 2016 B2
9474905 Doan et al. Oct 2016 B2
9700725 Zhu Jul 2017 B2
9724513 Lane et al. Aug 2017 B2
9737717 Moffitt et al. Aug 2017 B2
9802052 Marnfeldt Oct 2017 B2
9827422 Zhu Nov 2017 B2
9950170 Libbus et al. Apr 2018 B2
9981134 Doan et al. May 2018 B2
10118036 Zhu Nov 2018 B2
10118040 Zhu Nov 2018 B2
10195439 Steinke et al. Feb 2019 B2
10207109 Zhu et al. Feb 2019 B2
10213608 Moffitt Feb 2019 B2
10258797 Zhu Apr 2019 B2
10335599 Zottola Jul 2019 B2
10335601 Wechter et al. Jul 2019 B2
10449360 Moffitt et al. Oct 2019 B2
10456586 Wechter et al. Oct 2019 B2
10507328 Zhu Dec 2019 B2
10940314 Zhu et al. Mar 2021 B2
11224750 Zhu Jan 2022 B2
11684779 Zhu Jun 2023 B2
20020077669 Lindh et al. Jun 2002 A1
20020077859 Stahmann et al. Jun 2002 A1
20020115939 Mulligan et al. Aug 2002 A1
20020143365 Herbst Oct 2002 A1
20030139781 Bradley et al. Jul 2003 A1
20030176899 Samuelsson et al. Sep 2003 A1
20030212440 Boveja Nov 2003 A1
20040034394 Woods et al. Feb 2004 A1
20040111131 Hu et al. Jun 2004 A1
20040116978 Bradley Jun 2004 A1
20040267333 Kronberg Dec 2004 A1
20050060008 Goetz Mar 2005 A1
20050177206 North et al. Aug 2005 A1
20050267546 Parramon et al. Dec 2005 A1
20060015153 Gliner et al. Jan 2006 A1
20060149337 John Jul 2006 A1
20060241720 Woods et al. Oct 2006 A1
20060259078 Libbus Nov 2006 A1
20070027486 Armstrong Feb 2007 A1
20070142874 John Jun 2007 A1
20070150036 Anderson Jun 2007 A1
20070167991 DiLorenzo Jul 2007 A1
20070168004 Walter Jul 2007 A1
20070168007 Kuzma et al. Jul 2007 A1
20070213783 Pless Sep 2007 A1
20070225765 King Sep 2007 A1
20070299663 Fado et al. Dec 2007 A1
20080077192 Harry et al. Mar 2008 A1
20080158175 Hotelling et al. Jul 2008 A1
20080163097 Goetz et al. Jul 2008 A1
20080188909 Bradley Aug 2008 A1
20080243204 Uthman et al. Oct 2008 A1
20090024189 Lee et al. Jan 2009 A1
20090043359 Smoorenburg Feb 2009 A1
20090118777 Iki et al. May 2009 A1
20090196472 Goetz et al. Aug 2009 A1
20090198305 Naroditsky et al. Aug 2009 A1
20090198306 Goetz et al. Aug 2009 A1
20090204173 Fang et al. Aug 2009 A1
20100010390 Skelton et al. Jan 2010 A1
20100010566 Thacker et al. Jan 2010 A1
20100010646 Drew et al. Jan 2010 A1
20100023090 Jaax et al. Jan 2010 A1
20100114196 Burnes et al. May 2010 A1
20100121409 Kothandaraman et al. May 2010 A1
20100152817 Gillbe Jun 2010 A1
20100249875 Kishawi et al. Sep 2010 A1
20100274312 Alataris et al. Oct 2010 A1
20100274314 Alataris et al. Oct 2010 A1
20100274315 Alataris et al. Oct 2010 A1
20100274316 Alataris et al. Oct 2010 A1
20100274317 Parker et al. Oct 2010 A1
20100274318 Walker et al. Oct 2010 A1
20100274326 Chitre et al. Oct 2010 A1
20100324630 Lee et al. Dec 2010 A1
20110009923 Lee Jan 2011 A1
20110040352 Gerber et al. Feb 2011 A1
20110046697 Gerber et al. Feb 2011 A1
20110054567 Lane et al. Mar 2011 A1
20110054570 Lane Mar 2011 A1
20110093051 Davis et al. Apr 2011 A1
20110106214 Carbunaru et al. May 2011 A1
20110125223 Carbunaru et al. May 2011 A1
20110160810 Griffith Jun 2011 A1
20110184486 De Ridder Jul 2011 A1
20110184488 De Ridder Jul 2011 A1
20110201977 Tass Aug 2011 A1
20110208012 Gerber et al. Aug 2011 A1
20110213440 Fowler et al. Sep 2011 A1
20110213442 Pless Sep 2011 A1
20110282414 Kothandaraman et al. Nov 2011 A1
20110295332 Osorio Dec 2011 A1
20120016437 Alataris et al. Jan 2012 A1
20120059446 Wallace et al. Mar 2012 A1
20120083709 Parker et al. Apr 2012 A1
20120101547 Jensen et al. Apr 2012 A1
20120109006 James et al. May 2012 A1
20120184801 Simon Jul 2012 A1
20120197336 Su Aug 2012 A1
20120203304 Alataris et al. Aug 2012 A1
20120215279 Libbus Aug 2012 A1
20120253422 Thacker et al. Oct 2012 A1
20120265267 Blum et al. Oct 2012 A1
20120265279 Zhu et al. Oct 2012 A1
20120283797 De Ridder Nov 2012 A1
20120290041 Kim et al. Nov 2012 A1
20120296395 Hamann et al. Nov 2012 A1
20120296396 Moffitt et al. Nov 2012 A1
20120302912 Moffitt et al. Nov 2012 A1
20130018437 De Ridder Jan 2013 A1
20130041283 Wichner Feb 2013 A1
20130041425 Fang et al. Feb 2013 A1
20130053926 Hincapie Ordonez et al. Feb 2013 A1
20130060304 Wichner Feb 2013 A1
20130066411 Thacker et al. Mar 2013 A1
20130116752 Parker et al. May 2013 A1
20130131760 Rao et al. May 2013 A1
20130226261 Sparks et al. Aug 2013 A1
20130268021 Moffitt Oct 2013 A1
20130268026 Rao et al. Oct 2013 A1
20130296975 Lee et al. Nov 2013 A1
20130304152 Bradley et al. Nov 2013 A1
20140005743 Giuffrida et al. Jan 2014 A1
20140005744 Hershey et al. Jan 2014 A1
20140005753 Carbunaru Jan 2014 A1
20140031902 Mashiach et al. Jan 2014 A1
20140046398 Sachs et al. Feb 2014 A1
20140046407 Ben-Ezra et al. Feb 2014 A1
20140052033 Lawlis et al. Feb 2014 A1
20140067016 Kaula et al. Mar 2014 A1
20140074179 Heldman et al. Mar 2014 A1
20140074180 Heldman et al. Mar 2014 A1
20140074190 Griffith Mar 2014 A1
20140081349 Lee et al. Mar 2014 A1
20140081354 Davis et al. Mar 2014 A1
20140088674 Bradley Mar 2014 A1
20140172045 Yip et al. Jun 2014 A1
20140213926 Vaidyanathan Jul 2014 A1
20140222100 Libbus et al. Aug 2014 A1
20140222104 Smith Aug 2014 A1
20140222113 Gliner et al. Aug 2014 A1
20140243923 Doan et al. Aug 2014 A1
20140243924 Zhu et al. Aug 2014 A1
20140243925 Kothandaraman Aug 2014 A1
20140257425 Arcot-krishnamurthy et al. Sep 2014 A1
20140257428 Zhu Sep 2014 A1
20140276181 Sun et al. Sep 2014 A1
20140277267 Vansickle et al. Sep 2014 A1
20140330345 John Nov 2014 A1
20140364920 Doan et al. Dec 2014 A1
20140364921 Legay et al. Dec 2014 A1
20150012057 Carlson et al. Jan 2015 A1
20150051666 Roy et al. Feb 2015 A1
20150165209 Grandhe et al. Jun 2015 A1
20150217117 Hershey Aug 2015 A1
20150224307 Bolea Aug 2015 A1
20150238762 Pal et al. Aug 2015 A1
20150297893 Kokones et al. Oct 2015 A1
20150328461 Charlesworth et al. Nov 2015 A1
20150328462 Griffith Nov 2015 A1
20150328467 Demers et al. Nov 2015 A1
20150343242 Tyler et al. Dec 2015 A1
20160001087 Moffitt Jan 2016 A1
20160008604 Doan et al. Jan 2016 A1
20160027293 Esteller et al. Jan 2016 A1
20160074662 Moffitt et al. Mar 2016 A1
20160074663 De Ridder Mar 2016 A1
20160106985 Zhu Apr 2016 A1
20160121126 Marnfeldt May 2016 A1
20160129247 Lee et al. May 2016 A1
20160243366 Zhu et al. Aug 2016 A1
20160250472 Carbunaru Sep 2016 A1
20160279422 Libbus et al. Sep 2016 A1
20160279429 Hershey et al. Sep 2016 A1
20160346546 Zhu Dec 2016 A1
20170036030 Doan et al. Feb 2017 A1
20170050033 Wechter Feb 2017 A1
20170106197 Wechter et al. Apr 2017 A1
20170143964 Zhu May 2017 A1
20170266447 Zhu Sep 2017 A1
20170304636 Steinke et al. Oct 2017 A1
20170326365 Lane et al. Nov 2017 A1
20170333718 Moffitt et al. Nov 2017 A1
20180104488 Zhu Apr 2018 A1
20190038901 Zhu Feb 2019 A1
20190054306 Steinke et al. Feb 2019 A1
20190126029 Cheeran et al. May 2019 A1
20190160295 Moffitt May 2019 A1
20190184169 Zhu Jun 2019 A1
20190184180 Zhang et al. Jun 2019 A1
20190262622 Wechter Aug 2019 A1
20190329024 Kothandaraman et al. Oct 2019 A1
20190366107 Moffitt Dec 2019 A1
20200078593 Zhu Mar 2020 A1
20200147397 Huertas Fernandez et al. May 2020 A1
20210146138 Zhu May 2021 A1
20210146139 Zhu May 2021 A1
20220184400 Zhu Jun 2022 A1
Foreign Referenced Citations (67)
Number Date Country
2014218709 May 2018 AU
2015318142 Jun 2018 AU
2015343483 Jun 2018 AU
2016297965 Apr 2019 AU
2016268007 Aug 2019 AU
2019203787 Oct 2020 AU
2020289746 Jan 2023 AU
1980610 Jun 2007 CN
201139869 Oct 2008 CN
101610735 Dec 2009 CN
101687093 Mar 2010 CN
102413870 Apr 2012 CN
1956751 Aug 2012 CN
102725023 Oct 2012 CN
202933390 May 2013 CN
203777499 Aug 2014 CN
105163801 Dec 2015 CN
105188838 Apr 2017 CN
106687173 May 2017 CN
107073269 Aug 2017 CN
105163801 Nov 2017 CN
107921255 Apr 2018 CN
107921261 Apr 2018 CN
108463266 Aug 2018 CN
107073269 May 2020 CN
107921261 Jan 2022 CN
3328481 May 2019 EP
3302690 Sep 2019 EP
2449546 Nov 2008 GB
1057508 Mar 1998 JP
2004181100 Jul 2004 JP
2006116332 May 2006 JP
2010523215 Jul 2010 JP
2010527675 Aug 2010 JP
2010534114 Nov 2010 JP
2013533092 Aug 2013 JP
2014518722 Aug 2014 JP
2015521532 Jul 2015 JP
2016507334 Mar 2016 JP
2016507335 Mar 2016 JP
6163549 Jun 2017 JP
2017527429 Sep 2017 JP
2017533072 Nov 2017 JP
6400028 Sep 2018 JP
6452936 Dec 2018 JP
WO-03051175 Jun 2003 WO
WO-3051175 Jun 2003 WO
WO-2006029257 Mar 2006 WO
WO-2006135791 Dec 2006 WO
WO-2008095185 Aug 2008 WO
WO-2009067610 May 2009 WO
WO-2011082071 Jul 2011 WO
WO-2014130858 Aug 2014 WO
WO-2014130865 Aug 2014 WO
WO-2014159880 Oct 2014 WO
WO-2014197596 Dec 2014 WO
WO-2015119768 Aug 2015 WO
WO-20150119768 Aug 2015 WO
WO-2016004230 Jan 2016 WO
WO-2016044169 Mar 2016 WO
WO-2016073271 May 2016 WO
WO-2016154375 Sep 2016 WO
WO-2016172239 Oct 2016 WO
WO-2016191055 Dec 2016 WO
WO-2017019191 Feb 2017 WO
WO-2017066187 Apr 2017 WO
WO-2022132380 Jun 2022 WO
Non-Patent Literature Citations (223)
Entry
““U.S. Appl. No. 15/818,186, Notice of Allowance mailed Jul. 5, 2018””, 8 pgs.
“U.S. Appl. No. 14/195,632, Non Final Office Action mailed Mar. 18, 2015”, 6 pgs.
“U.S. Appl. No. 14/195,632, Notice of Allowance mailed Jun. 26, 2015”, 5 pgs.
“U.S. Appl. No. 14/195,632, Response filed Jun. 18, 2015 to Non Final Office Action mailed Mar. 18, 2015”, 10 pgs.
“U.S. Appl. No. 14/600,649, Non Final Office Action mailed Oct. 1, 2015”, 12 pgs.
“U.S. Appl. No. 14/600,649, Notice of Allowance mailed Mar. 7, 2016”, 8 pgs.
“U.S. Appl. No. 14/600,649, Response filed Jan. 4, 2016 to Non Final Office Action mailed Oct. 1, 2015”, 8 pgs.
“U.S. Appl. No. 14/920,229, Final Office Action mailed Aug. 16, 2016”, 8 pgs.
“U.S. Appl. No. 14/920,229, Non Final Office Action mailed May 3, 2016”, 8 pgs.
“U.S. Appl. No. 14/920,229, Notice of Allowability mailed Dec. 1, 2016”, 2 pgs.
“U.S. Appl. No. 14/920,229, Notice of Allowance mailed Mar. 3, 2017”, 5 pgs.
“U.S. Appl. No. 14/920,229, Notice of Allowance mailed Nov. 15, 2016”, 6 pgs.
“U.S. Appl. No. 14/920,229, Preliminary Amendment filed Jan. 13, 2016”, 7 pgs.
“U.S. Appl. No. 14/920,229, Response filed Aug. 3, 2016 to Non Final Office Action mailed May 3, 2016”, 8 pgs.
“U.S. Appl. No. 15/146,145, Non Final Office Action mailed Jan. 11, 2017”, 7 pgs.
“U.S. Appl. No. 15/146,145, Notice of Allowance mailed Jul. 28, 2017”, 8 pgs.
“U.S. Appl. No. 15/146,145, Response filed Apr. 11, 2017 to Non Final Office Action mailed Jan. 11, 2017”, 9 pgs.
“U.S. Appl. No. 15/426,776, Final Office Action mailed Apr. 17, 2018”, 5 pgs.
“U.S. Appl. No. 15/426,776, Non Final Office Action mailed Dec. 29, 2017”, 7 pgs.
“U.S. Appl. No. 15/426,776, Notice of Allowance mailed Jul. 6, 2018”, 5 pgs.
“U.S. Appl. No. 15/426,776, Preliminary Amendment filed Feb. 8, 2017”, 7 pgs.
“U.S. Appl. No. 15/426,776, Response filed Mar. 22, 2018 to Non Final Office Action mailed Dec. 29, 2017”, 9 pgs.
“U.S. Appl. No. 15/426,776, Response filed Jun. 18, 2018 to Final Office Action mailed Apr. 17, 2018”, 7 pgs.
“U.S. Appl. No. 15/615,046, Examiner Interview Summary mailed Mar. 22, 2019”, 3 pgs.
“U.S. Appl. No. 15/615,046, Examiner Interview Summary mailed May 29, 2019”, 3 pgs.
“U.S. Appl. No. 15/615,046, Final Office Action mailed Apr. 4, 2019”, 7 pgs.
“U.S. Appl. No. 15/615,046, Non Final Office Action mailed Dec. 3, 2018”, 7 pgs.
“U.S. Appl. No. 15/615,046, Notice of Allowance mailed Aug. 14, 2019”, 7 pgs.
“U.S. Appl. No. 15/615,046, Preliminary Amendment filed Jun. 7, 2017”, 6 pgs.
“U.S. Appl. No. 15/615,046, Response filed Jul. 3, 2019 to Final Office Action mailed Apr. 4, 2019”, 8 pgs.
“U.S. Appl. No. 15/615,046. Non-Final Office Action Response Filed Mar. 21, 2019”, 15 pgs.
“U.S. Appl. No. 15/818,186, Non Final Office Action mailed Feb. 13, 2018”, 7 pgs.
“U.S. Appl. No. 15/818,186, Preliminary Amendment filed Jan. 8, 2018”, 7 pgs.
“U.S. Appl. No. 15/818,186, Response filed May 7, 2018 to Non Final Office Action mailed Feb. 13, 2018”, 7 pgs.
“U.S. Appl. No. 16/156,224, Notice of Allowance mailed Dec. 4, 2018, 7 pgs”.
“U.S. Appl. No. 16/284,525, Non Final Office Action mailed Jul. 16, 2020”, 5 pgs.
“U.S. Appl. No. 16/284,525, Notice of Allowance mailed Nov. 2, 2020”, 7 pgs.
“U.S. Appl. No. 16/284,525, Response filed Sep. 29, 2020 to Non Final Office Action mailed Jul. 16, 2020”, 6 pgs.
“U.S. Appl. No. 16/686,956, Non Final Office Action mailed May 18, 2021”, 8 pgs.
“U.S. Appl. No. 16/686,956, Notice of Allowance mailed Sep. 13, 2021”, 5 pgs.
“U.S. Appl. No. 16/686,956, Preliminary Amendment Filed Nov. 20, 2019”, 6 pgs.
“U.S. Appl. No. 16/686,956, Response filed Aug. 2, 2021 to Non Final Office Action mailed May 18, 2021”, 8 pgs.
“U.S. Appl. No. 14/920,229, Response filed Oct. 17, 2016 to Final Office Action mailed Aug. 16, 2016”, 10 pgs.
“Australian Application Serial No. 2016268007, First Examination Report mailed Apr. 5, 2018”, 3 pgs.
“Australian Application Serial No. 2016268007, Response filed Mar. 25, 2019 to First Examination Report mailed Apr. 5, 2018”, 15 pgs.
“Australian Application Serial No. 2019203787, First Examination Report mailed Nov. 29, 2019”, 3 pgs.
“Australian Application Serial No. 2019203787, Response filed Sep. 11, 2020 to First Examination Report mailed Nov. 29, 2019”, no amendments were made, no arguments, only postponement of acceptance withdrawn., 1 pg.
“Chinese Application Serial No. 201680042569.1, Office Action mailed Sep. 2, 2020”, w/ English translation, 19 pgs.
“Chinese Application Serial No. 201680042569.1, Response filed Jan. 8, 2021 to Office Action mailed Sep. 2, 2020”, w/ English Claims, 4 pgs.
“European Application Serial No. 16725275.8, Response filed Aug. 29, 2018 to Communication Pursuant to Rules 161 and 162 EPC mailed Feb. 27, 2018”, 30 pgs.
“International Application Serial No. PCT/US2015/012030, International Search Report mailed Apr. 21, 2015”, 5 pgs.
“International Application Serial No. PCT/US2015/012030, Written Opinion mailed Apr. 21, 2015”, 7 pgs.
“International Application Serial No. PCT/US2016/030686, International Preliminary Report on Patentability mailed Dec. 7, 2017”, 8 pgs.
“International Application Serial No. PCT/US2016/030686, International Search Report mailed Jul. 25, 2016”, 4 pgs.
“International Application Serial No. PCT/US2016/030686, Written Opinion mailed Jul. 25, 2016”, 6 pgs.
Warman, Eduardo N., et al., “Modeling the Effects of Electric Fields on Nerve Fibers: Determination of Excitation Thresholds”, IEEE Transactions on Biomedical Engineering, vol. 39, No. 12, Dec. 1992, (Dec. 1992).
U.S. Appl. No. 14/195,632 U.S. Pat. No. 9,174,053, filed Mar. 3, 2014, Neuromodulation Using Modulated Pulse Train.
U.S. Appl. No. 14/920,229 U.S. Pat. No. 9,700,725, filed Oct. 22, 2015, Neuromodulation Using Modulated Pulse Train.
U.S. Appl. No. 15/426,776 U.S. Pat. No. 10,118,040, filed Feb. 7, 2017, Neuromodulation Using Modulated Pulse Train.
U.S. Appl. No. 15/615,046 U.S. Pat. No. 10,507,328, filed Jun. 6, 2017, Neuromodulation Using Modulated Pulse Train.
U.S. Appl. No. 16/686,956, filed Nov. 18, 2019, Neuromodulation Using Modulated Pulse Train.
U.S. Appl. No. 15/146,145 U.S. Pat. No. 9,827,422. filed May 4, 2016, Neuromodulation Using Stochastically-Modulated Stimulation Parameters.
U.S. Appl. No. 15/818,186 U.S. Pat. No. 10,118,036, filed Nov. 20, 2017, Neuromodulation Using Stochastically-Modulated Stimulation Parameters.
U.S. Appl. No. 16/156,224 U.S. Pat. No. 10,258,797, filed Oct. 10, 2018, Neuromodulation Using Stochastically-Modulated Stimulation Parameters.
U.S. Appl. No. 16/284,525 U.S. Pat. No. 10,940,314, filed Feb. 25, 2019, Neuromodulation Using Stochastically-Modulated Stimulation Parameters.
U.S. Appl. No. 17/157,659, filed Jan. 25, 2021, Neuromodulation Using Stochastically-Modulated Stimulation Parameters.
U.S. Appl. No. 17/157,690, filed Jan. 25, 2021, Neuromodulation Using Stochastically-Modulated Stimulation Parameters.
“U.S. Appl. No. 14/186,885, Non Final Office Action mailed Feb. 4, 2015”, 9 pgs.
“U.S. Appl. No. 14/186,885, Notice of Allowance mailed May 22, 2015”, 10 pgs.
“U.S. Appl. No. 14/186,885, Response filed May 4, 2015 to Non Final Office Action mailed Feb. 4, 2015”, 8 pgs.
“U.S. Appl. No. 14/186,927, Final Office Action mailed Nov. 20, 2015”, 5 pgs.
“U.S. Appl. No. 14/186,927, Non Final Office Action mailed May 5, 2015”, 7 pgs.
“U.S. Appl. No. 14/186,927, Response filed Jan. 20, 2016 to Final Office Action mailed Nov. 20, 2015”, 8 pgs.
“U.S. Appl. No. 14/186,927, Response filed Aug. 4, 2015 to Non Final Office Action maield May 5, 2015”, 10 pgs.
“U.S. Appl. No. 14/853,589, Final Office Action mailed Jan. 18, 2017”, 12 pgs.
“U.S. Appl. No. 14/853,589, Non Final Office Action mailed Aug. 17, 2016”, 14 pgs.
“U.S. Appl. No. 14/853,589, Notice of Allowance mailed Apr. 17, 2017”, 5 pgs.
“U.S. Appl. No. 14/853,589, Response filed Mar. 14, 2017 to Final Office Action mailed Jan. 18, 2017”, 12 pgs.
“U.S. Appl. No. 14/853,589, Response filed Nov. 17, 2016 to Non Final Office Action mailed Aug. 17, 2016”, 12 pgs.
“U.S. Appl. No. 14/859,456, Non Final Office Action mailed Feb. 1, 2016”, 9 pgs.
“U.S. Appl. No. 14/859,456, Notice of Allowance mailed Jun. 22, 2016”, 7 pgs.
“U.S. Appl. No. 14/859,456, Preliminary Amendment filed Oct. 21, 2015”, 6 pgs.
“U.S. Appl. No. 14/859,456, Response filed May 2, 2016 to Non Final Office Action mailed Feb. 1, 2016”, 10 pgs.
“U.S. Appl. No. 14/926,725, Corrected Notice of Allowance mailed Jul. 17, 2017”, 2 pgs.
“U.S. Appl. No. 14/926,725, Non Final Office Action mailed Mar. 3, 2017”, 13 pgs.
“U.S. Appl. No. 14/926,725, Notice of Allowability mailed Jul. 28, 2017”, 2 pgs.
“U.S. Appl. No. 14/926,725, Notice of Allowance mailed Jun. 27, 2017”, 8 pgs.
“U.S. Appl. No. 14/926,725, Response filed May 25, 2017 to Non Final Office Action mailed Mar. 3, 2017”, 12 pgs.
“U.S. Appl. No. 15/079,340, Advisory Action mailed Apr. 8, 2019”, 3 pgs.
“U.S. Appl. No. 15/079,340, Advisory Action mailed Jun. 21, 2018”, 3 pgs.
“U.S. Appl. No. 15/079,340, Examiner Interview Summary mailed Mar. 5, 2019”, 3 pgs.
“U.S. Appl. No. 15/079,340, Examiner Interview Summary mailed Jun. 17, 2019”, 3 pgs.
“U.S. Appl. No. 15/079,340, Final Office Action mailed Jan. 10, 2019”, 13 pgs.
“U.S. Appl. No. 15/079,340, Final Office Action mailed Apr. 4, 2018”, 12 pgs.
“U.S. Appl. No. 15/079,340, Non Final Office Action mailed May 13, 2019”, 13 pgs.
“U.S. Appl. No. 15/079,340, Non Final Office Action mailed Jul. 27, 2018”, 12 pgs.
“U.S. Appl. No. 15/079,340, Non Final Office Action mailed Oct. 3, 2017”, 10 pgs.
“U.S. Appl. No. 15/079,340, Response filed Mar. 4, 2019 to Final Office Action mailed Jan. 10, 2019”, 12 pgs.
“U.S. Appl. No. 15/079,340, Response filed Jun. 4, 2018 to Final Office Action mailed Apr. 4, 2018”, 10 pgs.
“U.S. Appl. No. 15/079,340, Response filed Oct. 29, 2018 to Non Final Office Action mailed Jul. 27, 2018”, 10 pgs.
“U.S. Appl. No. 15/079,340, Response filed Dec. 20, 2017 to Non Final Office Action mailed Oct. 3, 2017”, 10 pgs.
“U.S. Appl. No. 15/079,340, Supplemental Amendment and Response Apr. 10, 2019”, 14 pgs.
“U.S. Appl. No. 15/145,425, Response filed Mar. 22, 2018 to Non Final Office Aciton mailed Dec. 26, 2017”, 10 pgs.
“U.S. Appl. No. 15/145,425, Advisory Action mailed Nov. 6, 2017”, 3 pgs.
“U.S. Appl. No. 15/145,425, Examiner Interview Summary mailed Mar. 29, 2018”, 4 pgs.
“U.S. Appl. No. 15/145,425, Examiner Interview Summary mailed Sep. 18, 2018”, 3 pgs.
“U.S. Appl. No. 15/145,425, Final Office Action mailed Jul. 20, 2018”, 9 pgs.
“U.S. Appl. No. 15/145,425, Final Office Action mailed Jul. 26, 2017”, 9 pgs.
“U.S. Appl. No. 15/145,425, Non Final Office Action mailed Jan. 13, 2017”, 11 pgs.
“U.S. Appl. No. 15/145,425, Non Final Office Action mailed Dec. 26, 2017”, 8 pgs.
“U.S. Appl. No. 15/145,425, Notice of Allowance mailed Oct. 15, 2018”, 8 pgs.
“U.S. Appl. No. 15/145,425, Preliminary Amendment filed May 4, 2016”, 7 pgs.
“U.S. Appl. No. 15/145,425, Response filed Apr. 12, 2017 to Non Final Office Action mailed Jan. 13, 2017”, 10 pgs.
“U.S. Appl. No. 15/145,425, Response filed Sep. 19, 2018 to Final Office Action mailed Jul. 20, 2018”, 9 pgs.
“U.S. Appl. No. 15/145,425, Response filed Sep. 26, 2017 to Final Office Action mailed Jul. 26, 2017”, 9 pgs.
“U.S. Appl. No. 15/149,662, Advisory Action mailed Jan. 29, 2018”, 3 pgs.
“U.S. Appl. No. 15/149,662, Final Office Action mailed Nov. 24, 2017”, 11 pgs.
“U.S. Appl. No. 15/149,662, Non Final Office Action mailed Apr. 19, 2017”, 11 pgs.
“U.S. Appl. No. 15/149,662, Response filed Jan. 16, 2018 to Final Office Action mailed Nov. 24, 2017”, 19 pgs.
“U.S. Appl. No. 15/149,662, Response filed Aug. 21, 2017 to Non Final Office Action mailed Apr. 19, 2017”, 14 pgs.
“U.S. Appl. No. 15/180,980, Advisory Action mailed May 24, 2018”, 5 pgs.
“U.S. Appl. No. 15/180,980, Examiner Interview Summary mailed Apr. 30, 2018”, 3 pgs.
“U.S. Appl. No. 15/180,980, Examiner Interview Summary mailed Oct. 10, 2018”, 3 pgs.
“U.S. Appl. No. 15/180,980, Final Office Action mailed Mar. 1, 2018”, 10 pgs.
“U.S. Appl. No. 15/180,980, Non Final Office Action mailed Jul. 19, 2018”, 10 pgs.
“U.S. Appl. No. 15/180,980, Non Final Office Action mailed Sep. 21, 2017”, 9 pgs.
“U.S. Appl. No. 15/180,980, Repsonse filed Dec. 20, 2017 to Non Final Office Action mailed Sep. 21, 2017”, 15 pgs.
“U.S. Appl. No. 15/180,980, Response filed Jul. 2, 2018 to Advisory Action mailed May 24, 2018”, 11 pgs.
“U.S. Appl. No. 15/180,980, Response filed Oct. 8, 2018 to Non Final Office Action mailed Jul. 19, 2018”, 12 pgs.
“U.S. Appl. No. 15/290,776, Examiner Interview Summary mailed Oct. 12, 2018”, 3 pgs.
“U.S. Appl. No. 15/290,776, Non Final Office Action mailed Jul. 12, 2018”, 18 pgs.
“U.S. Appl. No. 15/290,776, Notice of Allowance mailed Apr. 24, 2019”, 8 pgs.
“U.S. Appl. No. 15/290,776, Response filed Oct. 8, 2018 to Non Final Office Action mailed Jul. 12, 2018”, 11 pgs.
“U.S. Appl. No. 15/290,776, Response filed Mar. 19, 2019 to Final Office Action mailed Jan. 31, 2019”, 8 pgs.
“U.S. Appl. No. 15/331,473, Non Final Office Action mailed Aug. 9, 2017”, 7 pgs.
“U.S. Appl. No. 15/331,473, Notice of Allowance mailed Feb. 1, 2018”, 7 pgs.
“U.S. Appl. No. 15/331,473, Preliminary Amendment filed Nov. 7, 2016”, 7 pgs.
“U.S. Appl. No. 15/331,473, Response filed Nov. 8, 2017 to Non Final Office Action mailed Aug. 9, 2017”, 8 pgs.
“U.S. Appl. No. 15/667,891, Preliminary Amendment filed Aug. 11, 2017”, 7 pgs.
“U.S. Appl. No. 15/670,328, Non Final Office Action mailed Apr. 24, 2019”, 7 pgs.
“U.S. Appl. No. 15/670,328, Notice of Allowance mailed Jun. 11, 2019”, 6 pgs.
“U.S. Appl. No. 15/670,328, Response filed Apr. 9, 2019 to Non Final Office Action mailed Jan. 14, 2019”, 11 pgs.
“U.S. Appl. No. 15/670,328, Response filed May 23, 2019 to Non Final Office Action mailed Apr. 24, 2019”, 8 Pgs.
“U.S. Appl. No. 17/157,659, Non Final Office Action mailed Dec. 1, 2023”, 14 pgs.
“U.S. Appl. No. 17/157,659, Preliminary Amendment filed Nov. 1, 2022”, 7 pgs.
“U.S. Appl. No. 17/157,659, Response filed Feb. 22, 2024 to Non Final Office Action mailed Dec. 1, 2023”, 10 pgs.
“U.S. Appl. No. 17/157,659, Response filed Sep. 19, 2023 to Restriction Requirement mailed Jul. 28, 2023”, 6 pgs.
“U.S. Appl. No. 17/157,659, Restriction Requirement mailed Jul. 28, 2023”, 7 pgs.
“U.S. Appl. No. 17/157,690, Non Final Office Action mailed Oct. 7, 2022”, 5 pgs.
“U.S. Appl. No. 17/157,690, Notice of Allowance mailed Feb. 21, 2023”, 8 pgs.
“U.S. Appl. No. 17/157,690, Resp onse filed Jan. 6, 2022 to Non Final Office Action mailed Oct. 7, 2022”, 6 pgs.
“U.S. Appl. No. 14/186,927, Notice of Allowance mailed Feb. 10, 2016”, 8 pgs.
“Australian Application Serial No. 2014218709, First Examiner Report mailed Jul. 31, 2017”, 3 pgs.
“Australian Application Serial No. 2014218709, Response filed Mar. 29, 2018 to First Examiner Report mailed Jul. 31, 2017”, 13 pgs.
“Australian Application Serial No. 2014218716, First Examiners Report mailed Aug. 4, 2017”, 2 pgs.
“Australian Application Serial No. 2014218716, Response filed Sep. 6, 2017 to First Examiners Report mailed Aug. 4, 2017”, 8 pgs.
“Australian Application Serial No. 2015318142, First Examiners Report mailed Sep. 15, 2017”, 3 pgs.
“Australian Application Serial No. 2015318142, Response filed Feb. 8, 2018 to First Examiners Report mailed Sep. 15, 2017”, 15 pgs.
“Australian Application Serial No. 2015343483, First Examiners Report mailed Sep. 19, 2017”, 3 pgs.
“Australian Application Serial No. 2015343483, Response filed Feb. 8, 2018 to First Examiners Report mailed Sep. 19, 2017”, 17 pgs.
“Australian Application Serial No. 2016297965, First Examination Report mailed Jun. 19, 2018”, 3 pgs.
“Australian Application Serial No. 2016297965, Response filed Feb. 22, 2019 to First Examination Report mailed Jun. 19, 2018”, 13 pgs.
“Australian Application Serial No. 2020289746, First Examination Report mailed Mar. 11, 2022”, 4 pgs.
“Australian Application Serial No. 2020289746, Response filled Nov. 17, 2022 to First Examination Report mailed Mar. 11, 2022”, 6 pgs.
“Chinese Application Serial No. 201480023455.3, Office Action mailed Apr. 19, 2017”, with English translation, 7 pages.
“Chinese Application Serial No. 201480023455.3, Office Action mailed Sep. 2, 2016”, with English translation, 13 pages.
“Chinese Application Serial No. 201480023455.3, Response filed Jan. 12, 2017 to Office Action mailed Sep. 2, 2016”, with English claims, 10 pages.
“Chinese Application Serial No. 201480023455.3, Response filed Jun. 21, 2017 to Office Action mailed Apr. 19, 2017”, with English claims, 8 pages.
“Chinese Application Serial No. 201480023467.6, Office Action mailed Aug. 9, 2016”, with machine English translation, 11 pages.
“Chinese Application Serial No. 201480023467.6, Response filed Dec. 19, 2016 to Office Action mailed Aug. 9, 2016”, with English claims, 117 pages.
“Chinese Application Serial No. 201580048568.3, Office Action mailed Mar. 28, 2019”, with English translation, 26 pages.
“Chinese Application Serial No. 201580048568.3, Office Action mailed Jul. 31, 2018”, with English translation, 24 pages.
“Chinese Application Serial No. 201580060184.3, Office Action mailed Aug. 2, 2019”, with English translation, 12 pages.
“Chinese Application Serial No. 201580060184.3, Response filed Oct. 9, 2019 to Office Action mailed Aug. 2, 2019”, with English claims, 14 pages.
“Chinese Application Serial No. 201580060184.3, Response to Examiner Telephone Interview filed Jan. 7, 2020”, with English claims, 13 pages.
“Chinese Application Serial No. 201680042569.1, Office Action mailed May 8, 2021”, with English translation, 14 pages.
“Chinese Application Serial No. 201680042569.1, Response filed Jun. 28, 2021 to Office Action mailed May 8, 2021”, with English claims, 51 pages.
“European Application Serial No. 13739318.7, Communication Pursuant to Article 94(3) EPC mailed Apr. 6, 2017”, 4 pgs.
“European Application Serial No. 13739318.7, Response filed Aug. 9, 2017 to Communication Pursuant to Article 94(3) EPC mailed Apr. 6, 2017”, 7 pgs.
“European Application Serial No. 14709103.7, Communication Pursuant to Article 94(3) EPC mailed Sep. 4, 2019”, 6 pgs.
“European Application Serial No. 14709103.7, Response filed Jan. 13, 2020 to Communication Pursuant to Article 94(3) EPC mailed Sep. 4, 2019”, 10 pgs.
“European Application Serial No. 15767069.6, Response filed Nov. 23, 2017 to Communication Pursuant to Rules 161 and 162 EPC mailed May 19, 2017”, 12 pgs.
“European Application Serial No. 15791183.5, Response filed Feb. 6, 2018 to Communication Pursuant to Rules 161 & 162 EPC mailed Jul. 27, 2017”, 12 pgs.
“European Application Serial No. 16732137.1, Response filed Oct. 15, 2018 to Communication Pursuant to Rules 161 and 162 EPC mailed Apr. 3, 2018”, 10 pgs.
“European Application Serial No. 18201843.2, Response filed Sep. 25, 2019 to Extended European Search Report mailed Jan. 2, 2019”, 10 pgs.
“International Application Serial No. PCT/US15/58017, International Search Report mailed Apr. 6, 2016”, 5 pgs.
“International Application Serial No. PCT/US15/58017, Written Opinion mailed Apr. 6, 2016”, 8 pgs.
“International Application Serial No. PCT/US2014/017777, International Preliminary Report on Patentability mailed Sep. 3, 2015”, 9 pgs.
“International Application Serial No. PCT/US2014/017777, International Search Report mailed May 13, 2014”, 6 pgs.
“International Application Serial No. PCT/US2014/017777, Written Opinion mailed May 13, 2014”, 7 pgs.
“International Application Serial No. PCT/US2014/017789, International Preliminary Report on Patentability mailed Sep. 3, 2015”, 7 pgs.
“International Application Serial No. PCT/US2014/017789, International Search Report mailed May 22, 2014”, 3 pgs.
“International Application Serial No. PCT/US2014/017789, Written Opinion mailed May 22, 2014”, 5 pgs.
“International Application Serial No. PCT/US2015/049993, International Preliminary Report on Patentability mailed Mar. 30, 2017”, 6 pgs.
“International Application Serial No. PCT/US2015/049993, International Search Report mailed Jan. 14, 2016”, 3 pgs.
“International Application Serial No. PCT/US2015/049993, Written Opinion mailed Jan. 14, 2016”, 4 pgs.
“International Application Serial No. PCT/US2015/058017, International Preliminary Report on Patentability mailed May 18, 2017”, 10 pgs.
“International Application Serial No. PCT/US2016/023888, International Preliminary Report on Patentability mailed Oct. 5, 2017”, 7 pgs.
“International Application Serial No. PCT/US2016/023888, International Search Report mailed Jun. 6, 2016”, 5 pgs.
“International Application Serial No. PCT/US2016/023888, Written Opinion mailed Jun. 6, 2016”, 5 pgs.
“International Application Serial No. PCT/US2016/037226, International Preliminary Report on Patentability mailed Feb. 8, 2018”, 7 pgs.
“International Application Serial No. PCT/US2016/037226, International Search Report mailed Aug. 25, 2016”, 4 pgs.
“International Application Serial No. PCT/US2016/037226, Written Opinion mailed Aug. 25, 2016”, 5 pgs.
“International Application Serial No. PCT/US2016/056426, International Preliminary Report on Patentability mailed Apr. 26, 2018”, 8 pgs.
“International Application Serial No. PCT/US2016/056426, International Search Report mailed Jan. 26, 2017”, 5 pgs.
“International Application Serial No. PCT/US2016/056426, Written Opinion mailed Jan. 26, 2017”, 6 pgs.
“International Application Serial No. PCT/US2021/059948, International Preliminary Report on Patentability mailed Jun. 29, 2023”, 10 pgs.
“International Application Serial No. PCT/US2021/059948, International Search Report mailed Mar. 3, 2022”, 5 pgs.
“International Application Serial No. PCT/US2021/059948, Written Opinion mailed Mar. 3, 2022”, 8 pgs.
“Japanese Application Serial No. 2015-559010, Examiners Decision of Final Refusal mailed Aug. 6, 2018”, with English translation, 6 pages.
“Japanese Application Serial No. 2015-559010, Office Action mailed Nov. 27, 2017”, with English translation, 6 pages.
“Japanese Application Serial No. 2015-559010, Response filed Feb. 27, 2018 to Office Action mailed Nov. 27, 2017”, with English claims, 7 pages.
“Japanese Application Serial No. 2015-559013, Office Action mailed Dec. 11, 2017”, with English translation, 5 pages.
“Japanese Application Serial No. 2015-559013, Response filed Mar. 9, 2018 to Office Action mailed Dec. 11, 2017”, with English claims, 8 pages.
“Japanese Application Serial No. 2017-533728, Office Action mailed Jan. 11, 2018”, with partial English translation, 8 pages.
“Japanese Application Serial No. 2017-542797, Office Action mailed May 21, 2018”, with English translation, 7 pages.
“Japanese Application Serial No. 2017-542797, Response filed Aug. 17, 2018 to Office Action mailed May 21, 2018”, with English claims, 9 pages.
Carlson, Dave, et al., “A Flexible Algorithm Framework for Closed-Loop Neuromodulation Research Systems”, Annual International Conference of the IEEE EMBS, (2013), 6146-6150.
Huiling, Zhao, et al., “A new type of intelligent electric stimulation”, Chinese Medical Equipment, vol. 8, Issue 10, (Oct. 31, 2011), 1-4.
Que, Doan T, et al., “Multi-Channel Neuromodulation System Having Frequency Modulation Stimulation”, U.S. Appl. No. 61/768,286, filed Feb. 22, 2013, 46 pages.
Rao, Prakash, et al., “Technique for Linking Electrodes Together During Programming of Neurostimulation System”, U.S. Appl. No. 61/561,760, filed Nov. 18, 2011, 62 pages.
VanSickle, Dennis Allen, et al., “Neuromodulation System and Method for Transitioning Between Programming Modes”, U.S. Appl. No. 14/214,752, filed Mar. 15, 2014, 159 pgs.
VanSickle, Dennis Allen, “Systems and Methods for Delivering Sub-Threshold Therapy to a Patient”, U.S. Appl. No. 61/801,917, filed Mar. 15, 2013, 124 pages.
Related Publications (1)
Number Date Country
20220118260 A1 Apr 2022 US
Provisional Applications (1)
Number Date Country
61774835 Mar 2013 US
Continuations (5)
Number Date Country
Parent 16686956 Nov 2019 US
Child 17562865 US
Parent 15615046 Jun 2017 US
Child 16686956 US
Parent 15426776 Feb 2017 US
Child 15615046 US
Parent 14920229 Oct 2015 US
Child 15426776 US
Parent 14195632 Mar 2014 US
Child 14920229 US